前列腺癌在台灣衛福部的統計資料中顯示為十大癌症死因之一，而在2016年美國男性癌症死亡的第二大原因。前列腺癌罹患機率會隨年紀漸長而增加。前列腺癌治療方式主要有手術切除、放射線治療、冷凍治療及賀爾蒙治療等，但由於人口高齡化及死亡率，因此需要尋求更有效的治療方式及藥物。本論文利用生物資訊來分析具有治療潛力的目標基因以及探討具有潛力的藥物，而在生物資訊方面，藉由Oncomine資料庫分析發現PDLIM5基因在前列腺癌檢體中有過度表現情形，進一步利用Survnexpress、PROGeneV2、PrognoScan及Cancer Cell Line Encyclopedia(CCLE) 資料庫分析，結果顯示當過度表現PDLIM5基因的病人其存活率明顯偏低。在藥物篩選方面我們分析了27個化合物，結果顯示第七號化合物對前列腺癌細胞株LNCaP及 PC-3細胞具有明顯毒殺效應。在未來進一步探討七號化合物抑制前列腺癌的訊息傳遞路徑及PDLIM5基因在前列腺癌發展中所扮演的角色，這些研究成果將有助於開發治療前列腺癌的潛力藥物。 Prostate cancer is one of the top ten cancer causes in the Ministry of Health department of Taiwan's statistics, and the second major cause of male cancer death in 2016 on the United States. The risk of having prostate cancer will increase with the age. Prostate cancer treatments are mainly included surgical resection, radiation therapy, cryotherapy and hormonal treatment, but we still need to find more effective treatments and drugs for against the population aging and mortality. In this study, we analyze the potential target gene by using bioinformatics and focus on research the potential drugs. In the bioinformatics analysis, overexpression of PDLIM5 in prostate cancer was determined by using Oncomine database. In addition, poor survival rate in PDLIM5 overexpression prostate cancer patients were observed form Survnexpress, PROGeneV2, PrognoScan and Cancer Cell Line Encyclopedia (CCLE) database. We analyzed 27 compounds and the results showed that compound No. 7 had better effects on prostate cancer cell lines LNCaP and PC-3 cells. Therefore, in the further study, we will try to investigate the signaling pathways of compound No. 7 and the role of PDLIM5 in prostate cancer cells. These results will be helpful on developing the potential drugs.
